论文部分内容阅读
胃癌是全球致死率第二高的恶性肿瘤,而胃癌发生腹膜转移复发是导致死亡的最重要原因之一。胃癌一旦出现腹膜转移则临床病理已属Ⅳ期,提示预后极差,通常中位生存期仅为3.5个月,即使切除原发肿瘤,中位总生存期也仅为9.5个月[1-2]。因此,对于胃癌腹膜转移复发的治疗已成为临床上十分棘手的难题,亟待采取更为有效的治疗措施,以进一步提高胃癌病人整体疗效。近20年来发展起来的腹腔内化
Gastric cancer is the second most common malignant tumor in the world. One of the most important causes of death is gastric cancer recurrence and peritoneal metastasis. Once peritoneal metastasis of gastric cancer, the clinical pathology is already stage Ⅳ, suggesting that the prognosis is very poor, usually median survival of only 3.5 months, even if the removal of the primary tumor, the median overall survival was only 9.5 months [1-2 ]. Therefore, the treatment of recurrence of peritoneal metastasis of gastric cancer has become a very difficult problem in clinical and urgent need to take more effective treatment measures to further improve the overall efficacy of gastric cancer patients. Nearly 20 years developed intraperitoneal